schliessen

Filtern

 

Bibliotheken

Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up

Lack of nucleos(t)ide analogue (NA) prophylaxis prior to chemotherapy is a common problem worldwide. The efficacy of newer-generation NAs in the rescue for the hepatitis B virus (HBV) reactivation has not been confirmed. We aimed to compare lamivudine (LVD) and entecavir (ETV) in the rescue of chemo... Full description

Journal Title: Journal of the Chinese Medical Association December 2017, Vol.80(12), pp.758-765
Main Author: Liao, Yi-Jun
Other Authors: Li, Yen-Chang , Lee, Shou-Wu , Wu, Chun-Ying , Yang, Sheng-Shun , Yeh, Hong-Zen , Chang, Chi-Sen , Lee, Teng-Yu
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1726-4901 ; E-ISSN: 1728-7731 ; DOI: 10.1016/j.jcma.2017.07.009
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_jcma_2017_07_009
title: Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
format: Article
creator:
  • Liao, Yi-Jun
  • Li, Yen-Chang
  • Lee, Shou-Wu
  • Wu, Chun-Ying
  • Yang, Sheng-Shun
  • Yeh, Hong-Zen
  • Chang, Chi-Sen
  • Lee, Teng-Yu
subjects:
  • Chemotherapy
  • Hepatic Failure
  • Immunosuppression
  • Nucleoside
  • Nucleotide
  • Medicine
ispartof: Journal of the Chinese Medical Association, December 2017, Vol.80(12), pp.758-765
description: Lack of nucleos(t)ide analogue (NA) prophylaxis prior to chemotherapy is a common problem worldwide. The efficacy of newer-generation NAs in the rescue for the hepatitis B virus (HBV) reactivation has not been confirmed. We aimed to compare lamivudine (LVD) and entecavir (ETV) in the rescue of chemotherapy-induced HBV flare-up. In this retrospective cohort study, we screened all HBV carriers who received therapeutic LVD or ETV for hepatitis flare-up after chemotherapy between January 1, 2004 and December 31, 2015. Patients who had other concurrent primary liver diseases such as chronic hepatitis C, who had baseline HBV viral load
language: eng
source:
identifier: ISSN: 1726-4901 ; E-ISSN: 1728-7731 ; DOI: 10.1016/j.jcma.2017.07.009
fulltext: fulltext
issn:
  • 1726-4901
  • 17264901
  • 1728-7731
  • 17287731
url: Link


@attributes
ID125874202
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_jcma_2017_07_009
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_jcma_2017_07_009
sourcesystemPC
dbid
0--K
1.FO
2.~1
30SF
41B1
51P~
61~.
7457
84G.
96I.
107-5
118P~
12AAFTH
13AAQFI
14ABBQC
15AEKER
16AEVXI
17AFTJW
18AGHFR
19AGYEJ
20AITUG
21AJRQY
22AJUYK
23EO8
24EO9
25EP2
26EP3
27FDB
28FIRID
29FNPLU
30GBLVA
31J1W
32LCYCR
33P-8
34P-9
35PC.
36Q38
37RPZ
38SDF
39SDG
40SEL
41SES
42SSZ
43Z5R
pqid1947098857
galeid523189160
display
typearticle
titleLamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
creatorLiao, Yi-Jun ; Li, Yen-Chang ; Lee, Shou-Wu ; Wu, Chun-Ying ; Yang, Sheng-Shun ; Yeh, Hong-Zen ; Chang, Chi-Sen ; Lee, Teng-Yu
ispartofJournal of the Chinese Medical Association, December 2017, Vol.80(12), pp.758-765
identifier
subjectChemotherapy ; Hepatic Failure ; Immunosuppression ; Nucleoside ; Nucleotide ; Medicine
descriptionLack of nucleos(t)ide analogue (NA) prophylaxis prior to chemotherapy is a common problem worldwide. The efficacy of newer-generation NAs in the rescue for the hepatitis B virus (HBV) reactivation has not been confirmed. We aimed to compare lamivudine (LVD) and entecavir (ETV) in the rescue of chemotherapy-induced HBV flare-up. In this retrospective cohort study, we screened all HBV carriers who received therapeutic LVD or ETV for hepatitis flare-up after chemotherapy between January 1, 2004 and December 31, 2015. Patients who had other concurrent primary liver diseases such as chronic hepatitis C, who had baseline HBV viral load <2000 IU/ml or data unavailable, or those who had primary or secondary liver cancers were excluded. By means of propensity scores, LVD users were randomly matched 1:1 with ETV users. Cumulative incidences of, and hazard ratios (HRs) for, mortality at 6 months were analyzed, and 1-year virological responses were evaluated....
languageeng
oafree_for_read
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://www.sciencedirect.com/science/article/pii/S1726490117302290$$EView_full_text_in_ScienceDirect
search
creatorcontrib
0Liao, Yi-Jun
1Li, Yen-Chang
2Lee, Shou-Wu
3Wu, Chun-Ying
4Yang, Sheng-Shun
5Yeh, Hong-Zen
6Chang, Chi-Sen
7Lee, Teng-Yu
titleLamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
description

Lack of nucleos(t)ide analogue (NA) prophylaxis prior to chemotherapy is a common problem worldwide. The efficacy of newer-generation NAs in the rescue for the hepatitis B virus (HBV) reactivation has not been confirmed. We aimed to compare lamivudine (LVD) and entecavir (ETV) in the rescue of chemotherapy-induced HBV flare-up.

In this retrospective cohort study, we screened all HBV carriers who received therapeutic LVD or ETV for hepatitis flare-up after chemotherapy between January 1, 2004 and December 31, 2015. Patients who had other concurrent primary liver diseases such as chronic hepatitis C, who had baseline HBV viral load <2000 IU/ml or data unavailable, or those who had primary or secondary liver cancers were excluded. By means of propensity scores, LVD users were randomly matched 1:1 with ETV users. Cumulative incidences of, and hazard ratios (HRs) for, mortality at 6 months were analyzed, and 1-year virological responses were evaluated.

...
subject
0Chemotherapy
1Hepatic Failure
2Immunosuppression
3Nucleoside
4Nucleotide
5Medicine
general
0English
1Elsevier Taiwan LLC
210.1016/j.jcma.2017.07.009
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_jcma_2017_07_009
issn
01726-4901
117264901
21728-7731
317287731
rsrctypearticle
creationdate2017
addtitleJournal of the Chinese Medical Association
searchscope
0elsevier_full
1elsevier4
2elsevier2
scope
0elsevier_full
1elsevier4
2elsevier2
lsr45$$EView_full_text_in_ScienceDirect
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1.FO
2.~1
30SF
41B1
51P~
61~.
7457
84G.
96I.
107-5
118P~
12AAFTH
13AAQFI
14ABBQC
15AEKER
16AEVXI
17AFTJW
18AGHFR
19AGYEJ
20AITUG
21AJRQY
22AJUYK
23EO8
24EO9
25EP2
26EP3
27FDB
28FIRID
29FNPLU
30GBLVA
31J1W
32LCYCR
33P-8
34P-9
35PC.
36Q38
37RPZ
38SDF
39SDG
40SEL
41SES
42SSZ
43Z5R
startdate20171201
enddate20171231
lsr40Journal of the Chinese Medical Association, December 2017, Vol.80 (12), pp.758-765
doi10.1016/j.jcma.2017.07.009
citationpf 758 pt 765 vol 80 issue 12
lsr30VSR-Enriched:[galeid, pqid]
sort
titleLamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
authorLiao, Yi-Jun ; Li, Yen-Chang ; Lee, Shou-Wu ; Wu, Chun-Ying ; Yang, Sheng-Shun ; Yeh, Hong-Zen ; Chang, Chi-Sen ; Lee, Teng-Yu
creationdate20171200
lso0120171200
facets
frbrgroupid3271634248008971783
frbrtype5
newrecords20190904
languageeng
topic
0Chemotherapy
1Hepatic Failure
2Immunosuppression
3Nucleoside
4Nucleotide
5Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Liao, Yi-Jun
1Li, Yen-Chang
2Lee, Shou-Wu
3Wu, Chun-Ying
4Yang, Sheng-Shun
5Yeh, Hong-Zen
6Chang, Chi-Sen
7Lee, Teng-Yu
jtitleJournal of the Chinese Medical Association
creationdate2017
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Liao
1Li
2Lee
3Wu
4Yang
5Yeh
6Chang
aufirst
0Yi-Jun
1Yen-Chang
2Shou-Wu
3Chun-Ying
4Sheng-Shun
5Hong-Zen
6Chi-Sen
7Teng-Yu
auinitY
auinit1Y
au
0Liao, Yi-Jun
1Li, Yen-Chang
2Lee, Shou-Wu
3Wu, Chun-Ying
4Yang, Sheng-Shun
5Yeh, Hong-Zen
6Chang, Chi-Sen
7Lee, Teng-Yu
atitleLamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up
jtitleJournal of the Chinese Medical Association
risdate201712
volume80
issue12
spage758
epage765
pages758-765
issn1726-4901
eissn1728-7731
formatjournal
genrearticle
ristypeJOUR
abstract

Lack of nucleos(t)ide analogue (NA) prophylaxis prior to chemotherapy is a common problem worldwide. The efficacy of newer-generation NAs in the rescue for the hepatitis B virus (HBV) reactivation has not been confirmed. We aimed to compare lamivudine (LVD) and entecavir (ETV) in the rescue of chemotherapy-induced HBV flare-up.

In this retrospective cohort study, we screened all HBV carriers who received therapeutic LVD or ETV for hepatitis flare-up after chemotherapy between January 1, 2004 and December 31, 2015. Patients who had other concurrent primary liver diseases such as chronic hepatitis C, who had baseline HBV viral load <2000 IU/ml or data unavailable, or those who had primary or secondary liver cancers were excluded. By means of propensity scores, LVD users were randomly matched 1:1 with ETV users. Cumulative incidences of, and hazard ratios (HRs) for, mortality at 6 months were analyzed, and 1-year virological responses were evaluated.

...
pubElsevier Taiwan LLC
doi10.1016/j.jcma.2017.07.009
lad01Journal of the Chinese Medical Association
oafree_for_read
date2017-12